EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Sphingolipids and Chronic Kidney Disease

Zrinka Šakić, Armin Atić iD, Slavica Potočki, Nikolina Bašić-Jukić iD

Journal of Clinical Medicine · 26.08.2024 · 13 (17) · 5050

DOI: 10.3390/jcm13175050 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 26.08.2024. Verfasst von Zrinka Šakić und 3 weiteren Autor:innen. Beteiligte Einrichtung: Vuk Vrhovac University Clinic, Dugi dol 4a, 10000 Zagreb, Croatia. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sphingolipids (SLs) are bioactive signaling molecules essential for various cellular processes, including cell survival, proliferation, migration, and apoptosis. Key SLs such as ceramides, sphingosine, and their phosphorylated forms play critical roles in cellular integrity. Dysregulation of SL levels is implicated in numerous diseases, notably chronic kidney disease (CKD). This review focuses on the role of SLs in CKD, highlighting their potential as biomarkers for early detection and prognosis. SLs maintain renal function by modulating the glomerular filtration barrier, primarily through the activity of podocytes. An imbalance in SLs can lead to podocyte damage, contributing to CKD progression. SL metabolism involves complex enzyme-catalyzed pathways, with ceramide serving as a central molecule in de novo and salvage pathways. Ceramides induce apoptosis and are implicated in oxidative stress and inflammation, while sphingosine-1-phosphate (S1P) promotes cell survival and vascular health. Studies have shown that SL metabolism disorders are linked to CKD progression, diabetic kidney disease, and glomerular diseases. Targeting SL pathways could offer novel therapeutic approaches for CKD. This review synthesizes recent research on SL signaling regulation in kidney diseases, emphasizing the importance of maintaining SL balance for renal health and the potential therapeutic benefits of modulating SL pathways.

Schlagwörter

Stichwörter der Autor:innen

ceramideschronic kidney diseasesphingolipidssphinogosine-1-phosphate

Autor:innen und Institutionen

  • Vuk Vrhovac University Clinic, Dugi dol 4a, 10000 Zagreb, Croatia.
  • Division of Nephrology, Arterial Hypertension, Dialysis and Transplantation, University Hospital Center Zagreb, 10000 Zagreb, Croatia.
  • School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.

ORCID-Profile: Armin Atić, Nikolina Bašić-Jukić

Zitieren

APA

Šakić, Z., Atić, A., Potočki, S., & Bašić-Jukić, N. (2024). Sphingolipids and Chronic Kidney Disease. Journal of Clinical Medicine, 13(17), 5050. https://doi.org/10.3390/jcm13175050

Vancouver

Šakić Z, Atić A, Potočki S, Bašić-Jukić N. Sphingolipids and Chronic Kidney Disease. Journal of Clinical Medicine. 2024;13(17):5050. doi:10.3390/jcm13175050

BibTeX
@article{aki2024,
  author = {Šakić, Zrinka and Atić, Armin and Potočki, Slavica and Bašić-Jukić, Nikolina},
  title = {Sphingolipids and Chronic Kidney Disease},
  journal = {Journal of Clinical Medicine},
  year = {2024},
  volume = {13},
  number = {17},
  pages = {5050},
  doi = {10.3390/jcm13175050}
}
Kostenlos starten →